Anti-CGRP compositions and use thereof

Patent metadata

Field	Value
Publication number	US-10533048-B2
Application number	US-201816117401-A
Country	US
Kind code	B2
Filing date	Aug 30, 2018
Priority date	May 20, 2011
Publication date	Jan 14, 2020
Grant date	Jan 14, 2020

Abstract

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

First claim

What is claimed is:

1. A method of treating an acute or chronic condition associated with elevated CGRP in a subject in need thereof comprising administering an effective amount of a humanized anti-calcitonin gene related polypeptide (CGRP) antibody comprising a variable light (V L ) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 57, and a variable heavy (V H ) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, and a pharmaceutically acceptable excipient.

2. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a V L chain polypeptide possessing at least 90% sequence identity to SEQ ID NO: 51 and a V H chain polypeptide possessing at least 90% sequence identity to SEQ ID NO: 53.

3. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a V L chain polypeptide of SEQ ID NO: 51 and a V H chain polypeptide of SEQ ID NO: 53.

4. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a light chain polypeptide of SEQ ID NO: 52 and heavy chain polypeptide of SEQ ID NO: 54.

5. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a human IgG1 constant domain.

6. The method of claim 1 , wherein the composition is intravenously administered.

7. The method of claim 2 , wherein the composition is intravenously administered.

8. The method of claim 3 , wherein the composition is intravenously administered.

9. The method of claim 4 , wherein the composition is intravenously administered.

10. The method of claim 5 , wherein the composition is suitable for intravenous administration.

11. The method of claim 1 , wherein the composition is intravenously administered.

12. The method of claim 2 , wherein the composition is intravenously administered.

13. The method of claim 3 , wherein the composition is subcutaneously administered.

14. The method of claim 4 , wherein the composition is subcutaneously administered.

15. The method of claim 5 , wherein the composition is subcutaneously administered.

16. The method of claim 1 , wherein the composition is an aqueous solution.

17. The method of claim 2 , wherein the composition is an aqueous solution.

18. The method of claim 3 , wherein the composition is an aqueous solution.

19. The method of claim 4 , wherein the composition is an aqueous solution.

20. The method of claim 5 , wherein the composition is an aqueous solution.

21. The method of claim 1 , wherein the composition is administered with another active agent.

22. The method of claim 2 , wherein the composition is administered with another active agent.

23. The method of claim 3 , wherein the composition is administered with another active agent.

24. The method of claim 4 , wherein the composition is administered with another active agent.

25. The method of claim 5 , wherein the composition is administered with another active agent.

26. The method of claim 21 , wherein the other active agent is an analgesic or anti-migraine drug.

27. The method of claim 22 , wherein the other active agent is an analgesic or anti-migraine drug.

28. The method of claim 23 , wherein the other active agent is an analgesic or anti-migraine drug.

29. The method of claim 24 , wherein the other active agent is an analgesic or anti-migraine drug.

30. The method of claim 25 , wherein the other active agent is an analgesic or anti-migraine drug.

Assignees

• Alderbio Holdings Llc

Inventors

• Kovacevich Brian Robert
• Garcia-Martinez Leon F
• Anderson Katie Olson
• Dutzar Benjamin H
• Billgren Jens J
• Latham John A
• Mitchell Danielle M
• Mcneill Patricia Dianne
• Janson Nicole M
• Loomis Maria-Cristina

Classifications

• C07K16/26 Primary

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title